Glenmark Pharmaceuticals has announced the launch of Empagliflozin and its fixed-drug combinations (FDCs) in India, strengthening its presence in the cardiometabolic segment. The new products will be marketed under the Glempa brand and its variants, Glempa-L and Glempa-M.
Key Highlights:
- Empagliflozin, an SGLT2 inhibitor, is widely used for managing Type 2 Diabetes Mellitus (T2DM).
- The drug helps in glycemic control, weight loss, and reducing cardiovascular and renal risks.
- Clinical studies have shown that Empagliflozin lowers cardiovascular mortality and hospitalization rates for heart failure (HF) patients.
- The EMPAREG clinical trial demonstrated a 14% reduction in major cardiovascular events among diabetes patients.
New Product Lineup:
- Glempa (Empagliflozin 10mg/25mg) – Standalone SGLT2 inhibitor to enhance glycemic control and lower cardiovascular risks.
- Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) – A combination of an SGLT2 inhibitor and DPP4 inhibitor, targeting diabetes with cardio-renal risks.
- Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg) – Designed for stronger glycemic control, combining Empagliflozin with Metformin.
Glenmark’s Legacy in Cardiometabolic Care
Glenmark has been a pioneer in launching affordable and innovative diabetes and cardiovascular treatments in India. The company previously introduced:
- Telmisartan (Telma) for hypertension.
- Teneligliptin (Zita Plus®) and its FDC with Metformin.
- Remogliflozin (Remo®) – A novel SGLT2 inhibitor.
- Sacubitril Valsartan (Sacu-V) for heart failure management.
Market Impact & Diabetes Prevalence in India
According to ICMR-INDIAB data, diabetes prevalence in India is estimated at 11.4%. The market size for Empagliflozin and its combinations is valued at ₹642 crore, while the total market for SGLT2 inhibitors is around ₹2,904 crore.
Glenmark’s new offerings aim to provide comprehensive and cost-effective solutions for millions of diabetes patients across India.
